Amplified, Off-the-Shelf Cancer-Killing Potential
Acepodia is focused on harnessing the potential of allogeneic natural killer (NK) cells as the primary chassis for its development approach and its initial lead cell therapy candidates. NK cells are a component of the body’s innate immune system and specialize in recognizing and attacking cancer cells.
Using its NK select screening platform, Acepodia has developed a unique line of off-the-shelf NK cells (oNK cells) that are further primed to fight cancer. oNK cells have a unique receptor expression profile with elevated levels of activating receptors (e.g., CD16) and low levels of inhibitory receptors, ensuring that they are primed and ready to engage cancer cells. Additionally, these cells are allogeneic, meaning they are produced outside of the body and represent a near-endless supply of cells that can be quickly and easily modified to develop potent cell therapies for cancer without needing to harvest the patient’s own immune cells.